EyePoint Announces Topline Results from LUCIA, the Second Pivotal Phase 3 Clinical Trial of DURAVYU™ in Wet AMD

Article summary

EyePoint, Inc. reported that its DURAVYU™ (vorolanib intravitreal insert) did not meet the primary endpoint of statistical non-inferiority in the LUCIA Phase 3 clinical trial for wet age-related macular degeneration.